Pasilan Renz Michael F, Villanueva Anthony Russell T
Division of Nephrology, Department of Medicine, Philippine General Hospital, University of the Philippines Manila.
Acta Med Philipp. 2024 Mar 22;58(5):68-73. doi: 10.47895/amp.vi0.7099. eCollection 2024.
Identical or Monozygotic twin kidney transplant usually possess an excellent immunological match and provide the opportunity to minimize or even avoid immunosuppression toxicity. However, there are concerns regarding disease recurrence among end stage kidney disease (ESKD) patients with an unknown etiology. Together with the risk of inherent, familial disease affecting donors and recipients alike, more invasive tests such as a pretransplant biopsy are being considered to ascertain renal prognosis. A 30-year-old female, known case of CKD Stage 5D from an unknown etiology, with secondary hyperparathyroidism and heart failure, presented at our OPD for kidney transplantation. Her donor is her identical twin who is asymptomatic and denies comorbidities. The recipient discloses a previous history of blood transfusion. Immunological workup revealed the following: matched blood type, zero HLA mismatch, negative T-cell tissue crossmatch but with a positive Class I HLA antigen screen. Antibody specificity revealed the presence of donor specific antibodies (DSA). After workup completion, the patient underwent a right kidney transplant with a preimplantation wedge biopsy on the donor kidney. Immediate graft function was noted post operatively. The wedge biopsy revealed a thinned glomerular basement membrane, consistent with Thin Basement Membrane Nephropathy (TBMN). The patient was started on immunosuppression and prophylaxis during the duration of the post operative period without any complications. Five months post-transplant, both the recipient and donor maintain an adequate renal function without any signs of allograft rejection. In this case report, we have demonstrated that TBMN may serve as a viable donor for a presumed monozygous twin kidney transplantation. When a live donor with TBMN is being considered, a thorough work-up and identification of high-risk features are essential to exclude other progressive renal diseases during the pretransplant evaluation.
同卵双胞胎肾移植通常具有极佳的免疫匹配度,并有机会将免疫抑制毒性降至最低甚至避免。然而,对于病因不明的终末期肾病(ESKD)患者,疾病复发仍令人担忧。加之存在影响供体和受体的遗传性家族疾病风险,人们正在考虑进行更具侵入性的检查,如移植前活检,以确定肾脏预后。一名30岁女性,因病因不明的慢性肾脏病5D期,伴有继发性甲状旁腺功能亢进和心力衰竭,前来我院门诊进行肾移植。她的供体是她的同卵双胞胎,供体无症状且否认有合并症。受体透露曾有输血史。免疫检查结果如下:血型匹配,HLA错配为零,T细胞组织交叉配型阴性,但I类HLA抗原筛查呈阳性。抗体特异性检测显示存在供体特异性抗体(DSA)。检查完成后,患者接受了右肾移植,并对供体肾进行了植入前楔形活检。术后立即观察到移植肾功能良好。楔形活检显示肾小球基底膜变薄,符合薄基底膜肾病(TBMN)。患者在术后期间开始接受免疫抑制和预防治疗,未出现任何并发症。移植后五个月,受体和供体肾功能均维持良好,无任何移植肾排斥迹象。在本病例报告中,我们证明了TBMN可作为假定的同卵双胞胎肾移植的可行供体。当考虑使用患有TBMN的活体供体时,在移植前评估中进行全面检查并识别高危特征对于排除其他进行性肾病至关重要。